Zydus Cadila finishes stage 2 preliminary, to submit information in November

Zydus Cadila finishes stage 2 preliminary, to submit information in November

Overview

  • Post By : Kumar Jeetendra

  • Source:

  • Date: 03 Nov,2020

Cadila Healthcare (Zydus Cadila) said it has completed enrolment and dosing of 1,000 volunteers in phase-2 clinical trials of its possible Covid-19 vaccine, ZyCoV-D, and plans to submit the data to the Drug Controller General of India (DCGI) this past month.

“At present the immunogenicity evaluation is going on,” said Sharvil Patel, Managing Director of Zydus Cadila, in an upgrade to analysts during the company’s earnings call on Monday.

Immunogenicity refers to the ability of the vaccine to provoke an immune reaction in the human body.

“We will have a readout (of phase 2) at the end of November, and immediately we’ll apply for phase-3 permission,” Patel added.

The Zydus Cadila MD reported that based on the regulator’s response, the company intends to start a bigger phase-3 trial in December, and expects to have final data by March-April 2021.

Zydus Cadila initiated Phase–1 and 2 trials in July. The business plans to test the ZyCoV-D vaccine on about 15,000-20,000 people in Phase-3. The initiation of the vaccine is expected in the first half of 2021.

Patel said no safety concerns were detected in phase-1. He added that cellular and humoral immunity response studies are under progress, together with neutralisation antibody testing related to phase-1.

Affordable vaccine

The company has taken a novel approach to its possible Covid-19 vaccine, using the DNA route. The DNA vaccine includes genetic material of SARS-CoV-2 proteins. The genetic material instructs human cells to make SARS-CoV2 antigen, eliciting an immune reaction.

The company says that this approach is easily replicable and scalable, requiring just Biosafety Level (BSL)-1, since the vaccine does not use any live virus.

Biosafety level 1 applies to laboratory settings and manufacturing plants where employees work with low-risk microbes that pose little to no danger of disease in humans.

“We don’t have any infectious agent as part of delivery technologies, DNA vaccines have a very clear pathway both from the WHO and USFDA in terms of requirements for safety and efficacy,” Patel said.

He added that the ZyCoV-D vaccine can be stored at 2-8 degrees temperature, making it an excellent fit for the existing cold chain infrastructure. The vaccine is delivered via the intradermal (injected into the skin ) path, which is much easier to administer compared to intramuscular injection, which requires training of healthcare workers.

Patel declined to provide an indication of the vaccine’s pricing, but said it would be affordable, given the inherent advantages of the technology utilized to develop it.

Pursuit of vaccine deals

Patel said the company is making conscious efforts to collaborate with multinational companies to manufacture and distribute their Covid-19 vaccines in India and emerging markets.

“We are making conscious efforts to collaborate with various multinational organisations to produce their vaccines available in India and emerging markets,” Patel explained.

“We have different platforms for (vaccine) manufacturing because we do multiple vaccines. So, some of them already have abilities to manufacture vaccines at small scale or initial scale. And if the vaccine is successful we can scale up those plants. There’ll be some investment, but we can begin technology transfer and initiate scaling up the process as the vaccines go through clinical phases,” he added.

Patel noted that it takes about 4-6 weeks to scale a vaccine from pilot scale to commercial manufacturing.

About Author